Hormonal
Liraglutide shows a statistically significant disproportionality signal for completed suicide, but this is likely due to statistical fragility, small case numbers, and notoriety bias rather than a true pharmacological effect.
While Liraglutide shows a statistical signal for completed suicide in reporting databases, this is based on a very small number of cases (14) and is likely influenced by reporting bias. It should not be interpreted as evidence of increased risk.
A statistically significant disproportionality signal for completed suicide was observed for liraglutide; however, this estimate was based on few cases and displayed wide confidence intervals, warranting cautious interpretation.
Why this rating
Based on only 14 cases with wide confidence intervals, making the estimate statistically unstable.
Source
Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs in the FDA Adverse Event Reporting System
Jose Seijas-Amigo et al. · International Journal of Clinical Pharmacy · 2026
DOI 10.1007/s11096-026-02099-y
More from this paper
- GLP-1 receptor agonists and dual incretin therapies (semaglutide, liraglutide, tirzepatide) do not show a disproportional reporting signal for suicidal ideation or suicide attempt compared to non-GLP-1 anti-obesity drugs.Moderate
- Non-GLP-1 anti-obesity drugs, specifically naltrexone/bupropion, show elevated disproportional reporting signals for suicidal ideation and suicide attempt compared to GLP-1/dual incretin therapies.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →